A detailed history of Price T Rowe Associates Inc transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 23,054 shares of KURA stock, worth $409,669. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,054
Previous 20,148 14.42%
Holding current value
$409,669
Previous $430,000 10.47%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$17.53 - $22.98 $50,942 - $66,779
2,906 Added 14.42%
23,054 $475,000
Q1 2024

May 15, 2024

BUY
$13.42 - $23.53 $39,454 - $69,178
2,940 Added 17.09%
20,148 $430,000
Q4 2023

Feb 14, 2024

SELL
$7.58 - $14.38 $133,855 - $253,936
-17,659 Reduced 50.65%
17,208 $248,000
Q3 2023

Nov 14, 2023

BUY
$8.44 - $11.86 $88,611 - $124,518
10,499 Added 43.09%
34,867 $318,000
Q2 2023

Aug 14, 2023

BUY
$9.62 - $13.99 $5,848 - $8,505
608 Added 2.56%
24,368 $258,000
Q1 2023

May 15, 2023

BUY
$10.71 - $14.6 $10,442 - $14,235
975 Added 4.28%
23,760 $291,000
Q4 2022

Feb 14, 2023

SELL
$11.23 - $16.9 $44,504 - $66,974
-3,963 Reduced 14.82%
22,785 $283,000
Q3 2022

Nov 14, 2022

SELL
$12.01 - $19.45 $132,686 - $214,883
-11,048 Reduced 29.23%
26,748 $366,000
Q2 2022

Aug 15, 2022

BUY
$10.71 - $18.33 $4,530 - $7,753
423 Added 1.13%
37,796 $693,000
Q1 2022

May 16, 2022

BUY
$11.78 - $16.98 $180,186 - $259,726
15,296 Added 69.28%
37,373 $601,000
Q4 2021

Feb 14, 2022

SELL
$12.22 - $19.57 $211,137 - $338,130
-17,278 Reduced 43.9%
22,077 $309,000
Q3 2021

Nov 15, 2021

BUY
$15.42 - $21.72 $97,701 - $137,617
6,336 Added 19.19%
39,355 $737,000
Q2 2021

Aug 16, 2021

BUY
$20.85 - $29.88 $26,542 - $38,037
1,273 Added 4.01%
33,019 $688,000
Q1 2021

May 17, 2021

BUY
$24.75 - $39.14 $196,119 - $310,145
7,924 Added 33.26%
31,746 $897,000
Q4 2020

Feb 16, 2021

BUY
$29.0 - $41.62 $690,838 - $991,471
23,822 New
23,822 $778,000

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $1.19B
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.